Jonathan Dickinson at the helm of Innate

Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) named Jonathan Dickinson chairman and CEO,  effective Nov. 1. Dickinson was EVP and general manager, Europe at Incyte Corp. (NASDAQ:INCY) and succeeds co-founder and interim CEO Hervé Brailly, who will continue as an adviser and be proposed as a board member. Innate is developing immunotherapies to treat cancer.

Regenerative medicines company  Sernova Corp. (TSX-V:SVA; OTCQX:SEOVF) named James Parsons CFO, Marylyn Rigby chief communications officer and David Burke VP of investor relations (IR). Parsons was CFO at Trillium Therapeutics Inc. and joined Sernova’s board in 2012; Rigby is CEO of Bioceptive Inc., and Burke was SVP, corporate strategy and IR at MedKick Inc...